Systemic Mastocytosis (DBCOND0028386)

Identifiers

Synonyms

Mastocytosis, Systemic / Systemic mastocytosis / Systemic mastocytosis (morphologic abnormality) / Malignant systemic mastocytosis (morphologic abnormality) / Systemic mast cell disease (disorder) / Isolated bone marrow mastocytosis (disorder) / Smoldering systemic mastocytosis (morphologic abnormality) / Smoldering systemic mastocytosis (disorder) / Indolent Systemic Mastocytosis / Indolent systemic mastocytosis (morphologic abnormality) / Indolent systemic mastocytosis (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cimetidine	A histamine H2 receptor antagonist used to manage GERD, peptic ulcer disease, and indigestion.	Histamine H2 receptortarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Solute carrier family 22 member 1transporter Solute carrier family 22 member 3transporter Organic cation/carnitine transporter 2transporter Solute carrier family 22 member 6transporter Organic anion transporter 3transporter Multidrug and toxin extrusion protein 1transporter Solute carrier family 22 member 4transporter Solute carrier family 22 member 11transporter Solute carrier family 22 member 7transporter Cytochrome P450 11B1, mitochondrialenzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2E1enzyme Flavin-containing monooxygenase 3enzyme Flavin-containing monooxygenase 1enzyme Bile salt export pumptransporter Multidrug and toxin extrusion protein 2transporter Albumincarrier
Midostaurin	An antineoplastic agent used to treat high-risk acute myeloid leukemia (AML) with specific mutations, aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL).	Protein kinase C alpha typetarget Vascular endothelial growth factor receptor 2target Mast/stem cell growth factor receptor Kittarget Platelet-derived growth factor receptor alphatarget Platelet-derived growth factor receptor betatarget Receptor-type tyrosine-protein kinase FLT3target Cytochrome P450 3A Subfamilyenzyme Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2E1enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Cytochrome P450 3A43enzyme Protein kinase C gamma typetarget
Omeprazole	A proton pump inhibitor used to treat GERD associated conditions such as heartburn and gastric acid hypersecretion, and to promote healing of tissue damage and ulcers caused by gastric acid and H. pylori infection.	Potassium-transporting ATPase alpha chain 1target Cytochrome P450 2C19enzyme Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Cytochrome P450 1A2enzyme ATP-binding cassette sub-family C member 3transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A1enzyme Cytochrome P450 1B1enzyme Cytochrome P450 2C18enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Aryl hydrocarbon receptortarget Potassium-transporting ATPase subunit betatarget
Ranitidine	A histamine H2 antagonist used to treat duodenal ulcers, Zollinger-Ellison syndrome, gastric ulcers, GERD, and erosive esophagitis.	Histamine H2 receptortarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Solute carrier family 22 member 1transporter ATP-dependent translocase ABCB1transporter Organic anion transporter 3transporter Cytochrome P450 3A4enzyme Acetylcholinesterasetarget Solute carrier family 22 member 2transporter Acetylcholinesteraseenzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06065007	Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis	No drug interventions	Not Available	Not Available	recruiting
NCT05186753	(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis	Bezuclastinib	treatment	2	recruiting
NCT04681105	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies	Acetaminophen Dexamethasone Diphenhydramine Flotetuzumab Ibuprofen Ranitidine	treatment	1	active_not_recruiting
NCT00109707	A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies	Nilotinib	treatment	1 / 2	completed
NCT00449748	Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis	Everolimus	treatment	2	completed
NCT00171912	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes	Imatinib	treatment	2	completed
NCT01297777	Imatinib in KIT-negative Systemic Mastocytosis	Imatinib	treatment	4	completed
NCT01807598	Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia	Brentuximab vedotin	treatment	2	completed
NCT03739606	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Flotetuzumab	treatment	2	withdrawn
NCT01334996	Use of Tamoxifen in Systemic Mastocytosis	No drug interventions	Not Available	Not Available	completed
NCT01602939	Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis	Benzalkonium Cladribine	treatment	2 / 3	unknown_status
NCT02478957	Treatment of Indolent Systemic Mastocytosis With PA101	No drug interventions	treatment	2	completed
NCT03214666	GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies	GTB-3550	treatment	1 / 2	terminated
NCT02441166	Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis	No drug interventions	diagnostic	Not Available	completed
NCT00918931	Obatoclax for Systemic Mastocytosis	Obatoclax	treatment	2	terminated
NCT03401060	Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis	Denosumab	treatment	3	completed
NCT00979160	Evaluation of Response of Dasatinib to Treat Mastocytosis	Dasatinib	treatment	2	unknown_status
NCT00493129	Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)	Denileukin diftitox	treatment	2	completed
NCT02415608	Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis	Ibrutinib	treatment	2	terminated